Fresenius Kabi launches Methocarbamol Injection in US for acute musculoskeletal conditions
Fresenius Kabi, the global German healthcare company, has unveiled Methocarbamol Injection, USP in the United States, marking a significant expansion of its anesthesia and analgesia ... Read More
Novus Therapeutics begins phase 1 trial of OP0201 in otitis media
Novus Therapeutics has launched a phase 1 pharmacodynamics clinical trial for its promising candidate, OP0201, aimed at treating otitis media—a common middle ear infection. The ... Read More
EC approves ADCETRIS for treating CD30+ Stage IV Hodgkin lymphoma
The European Commission (EC) has officially expanded the approval of Takeda Pharmaceutical's ADCETRIS (brentuximab vedotin) to include the treatment of previously untreated CD30+ Stage IV ... Read More
Dr. Henry’s Vitamins reveals game-changing Prenatal Plus and Omega-3 for Women
Dr. Henry’s Vitamins has unveiled its latest product offerings: the Prenatal Plus and Omega-3 for Women, crafted with pure, high-quality ingredients to ensure maximum absorption ... Read More
Samsung Bioepis partners with C-Bridge Capital to expand biosimilar portfolio in China
Samsung Bioepis, a South Korean leader in biopharmaceuticals, has struck a deal with private equity firm C-Bridge Capital to develop and commercialize next-generation biosimilars in ... Read More
Ablynx secures FDA approval for Cablivi to treat aTTP
In a significant milestone for Belgian biopharma company Ablynx, the U.S. Food and Drug Administration (FDA) has granted approval for Cablivi (caplacizumab-yhdp), a nanobody designed ... Read More
Pulmazole phase 2 clinical study gets FDA approval for Pulmazole in allergic bronchopulmonary aspergillosis
Pulmatrix, the Massachusetts-based biopharmaceutical company, has received approval from the US Food and Drug Administration (FDA) to initiate a phase 2 clinical trial for Pulmazole ... Read More
GSK completes $5.1bn acquisition of Tesaro to boost oncology pipeline
GlaxoSmithKline (GSK), the British pharmaceutical powerhouse, has successfully concluded its $5.1 billion acquisition of Tesaro, a leading oncology-focused biopharmaceutical company based in Waltham, Massachusetts. This ... Read More
BridgeBio Pharma secures $299m in funding to accelerate genetic disease drug development
BridgeBio Pharma, a leading clinical-stage biopharma company specialising in treatments for genetic diseases, has raised $299.2 million in a new funding round. The California-based firm ... Read More
Italian pharma company Newron completes patient enrollment for sarizotan STARS trial in Rett syndrome
Newron Pharmaceuticals, an Italian biotech company, has successfully completed patient enrollment in its pivotal STARS clinical trial, which is investigating sarizotan as a potential treatment ... Read More